Sleep disturbances impact a significant portion of the global adult population, with an estimated 50% experiencing disruptions in their sleep patterns. In the United States, the National Institutes of Health (NIH) reports that approximately 30-40% of adults complain of sleep disturbances. Insomnia stands out as the most prevalent sleep complaint among adults, affecting anywhere from 5% to 50% of the adult population in the U.S. The prevalence of chronic insomnia disorder is estimated to be between 6% and 23%. Additionally, obstructive sleep apnea (OSA) is identified as the most common type of sleep-disordered breathing (SDB), posing a significant risk factor for cardiovascular disease and motor vehicle crashes.
Recognizing the widespread impact of these conditions on patients with sleep disorders, the Veterans Health Administration/Department of Defense (VA/DoD) have recently updated their clinical guideline on the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. This update incorporates new research findings, clinical trials, and evolving treatment strategies. In this article, we will compare the 2025 and 2019 versions of the VA/DoD guideline, focusing on key differences in recommendations and the integration of new therapies. While we will not delve into every detail, we encourage readers to review the full guidelines provided below for a more comprehensive understanding.
Guidelines Referenced
- Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea
- Publication: February 2025
- Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea
- Publication: October 2019
Major Changes and Key Takeaways (2019 - 2025)
| 2019 Version | 2025 Version | Key Changes & Takeaways | |
|---|---|---|---|
| Chronic Insomnia Disorder (CID) | |||
| Behavioral Treatments | Cognitive Behavioral Therapy for Insomnia (CBT-I) as the gold standard. Focus on sleep restriction, cognitive restructuring, and stimulus control, relaxation therapy and counter arousal strategies, and sleep hygiene education. | CBT-I remains the gold standard, but with more emphasis on digital CBT-I programs and remote therapy options. | Digital health tools (e.g., apps, online therapy) are more integrated, improving accessibility and adherence. |
| Sleep Hygiene | Emphasis on educating patients about maintaining consistent sleep-wake times, avoiding caffeine, and creating a conducive sleep environment. | Similar, with added focus on avoiding excessive screen time and understanding the impact of light exposure on circadian rhythm. | The understanding of light exposure and technology’s impact on sleep is more refined in the 2025 version. |
| Pharmacologic Treatments | Short-term use of sedative-hypnotics (e.g., zolpidem) and melatonin receptor agonists. Trazodone and low-dose antidepressants are often used for chronic cases. | Use of melatonin receptor agonists (e.g., ramelteon) and low-dose antidepressants is more cautious. Non-benzodiazepine sedative hypnotics like eszopiclone are still used but with more attention to dependency risks. More focus on long-term non-pharmacologic treatments like CBT-I first. | Pharmacological treatments are still used but there is greater emphasis on non-pharmacological approaches first, reflecting a trend toward reducing medication dependency. |
| Emerging Therapies | Limited exploration of virtual sleep clinics and digital interventions. | A notable rise in the use of virtual consultations, sleep tracking apps, and telemedicine. These are integrated with behavioral therapies. | The integration of telemedicine and virtual interventions has seen significant growth. Digital therapeutics are playing a larger role in treating insomnia. |
| Obstructive Sleep Apnea (OSA) | |||
| Behavioral Treatments | Focus on lifestyle changes (weight loss, smoking cessation, alcohol avoidance) and positional therapy for mild OSA. | Lifestyle changes remain essential, but with greater emphasis on targeted weight loss interventions and exercise. More awareness of sleep position’s role in OSA. | There is an increased focus on exercise and targeted weight loss programs to treat OSA. Sleep positioning is becoming a more studied factor in OSA management. |
| Medical Devices | CPAP (Continuous Positive Airway Pressure) therapy is the primary treatment, with a strong focus on titrating CPAP pressure for optimal effectiveness. | CPAP remains the main treatment. There is now more focus on personalized CPAP settings, such as auto-titrating CPAP (APAP). Also, BiPAP and newer adaptive servo-ventilation (ASV) technologies are emerging. | There is a more personalized approach to CPAP settings and an increasing role for BiPAP and ASV, with more attention on comfort and adherence. |
| Mandibular Advancement Devices (MADs) | MADs are recommended for mild to moderate OSA, but CPAP is generally preferred for moderate-to-severe cases. | MADs are still recommended for mild-to-moderate OSA. There's now an emphasis on custom fitting to improve comfort and efficacy. | The customization of MADs has become more refined, with improved patient satisfaction and better outcomes in mild to moderate cases. |
| Pharmacologic Treatments | Not typically used, but modafinil may be prescribed for excessive daytime sleepiness. | Pharmacological treatment for daytime sleepiness (modafinil, armodafinil) remains, but is increasingly combined with CBT-I or other non-pharmacological approaches for sleep maintenance. | There is a greater integration of non-pharmacological treatments (e.g., CBT-I) to manage daytime sleepiness, along with pharmacology as an adjunct. |
| Surgical Options | Surgery (e.g., UPPP, MMA) considered in severe cases. Focus on addressing structural obstructions in the upper airway. | Surgical interventions continue to be an option, but more minimally invasive procedures like hypoglossal nerve stimulation are gaining traction. | Minimally invasive options, like nerve stimulation, have emerged, offering less invasive alternatives to traditional surgery. |
Key Takeaways:
- Telemedicine and Digital Health:
- In the 2025 version, there is a notable increase in the use of digital health tools, including virtual CBT-I and sleep tracking apps, making treatment more accessible and tailored.
- Personalized Care:
- Both for insomnia and OSA, there’s a greater focus on personalized treatment, such as auto-titrating CPAP and custom MAD fittings, to improve patient comfort and adherence.
- Emphasis on Non-Pharmacological Approaches:
- For Chronic Insomnia, there’s a stronger push toward CBT-I and lifestyle modifications before medications. In OSA, lifestyle changes and exercise programs are given more attention.
- Surgical Innovations:
- In OSA, surgical options are evolving with the rise of minimally invasive techniques, such as hypoglossal nerve stimulation, reducing the need for more invasive surgeries like UPPP and MMA.
- Pharmacological Treatments:
- Pharmacological options are still available but increasingly used as adjuncts rather than primary treatments, especially with a focus on reducing dependency on medications.
In conclusion, the 2025 version signifies a transition towards personalized, minimally invasive, and technology-integrated strategies for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. It maintains the fundamental principles of management established in the 2019 version. Both iterations strive to offer thorough, evidence-based suggestions to enhance patient outcomes and the treatment of chronic insomnia disorder and OSA. The 2025 edition expands upon the 2019 guidelines by integrating recent research discoveries and therapeutic alternatives.
We are grateful for your ongoing interest, and we encourage you to stay informed about upcoming segments in our series. We value your feedback and would like to hear your suggestions for future topics to be covered in our guideline series. Please feel free to contact us with any ideas or questions you may have.
Sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2025 Guideline Central, All Rights Reserved.